tbuckley/cabot-search huggingface dataset:
Mutations in <i>BCOR</i>, <i>CCND2</i>, <i>NRAS</i> and <i>XPO1</i> Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia
Authors: Christian Brieghel, Julie Dubois, Ida Kappel Buhl, Kazem Nasserinejad, Dennis De Rooij, Karl Nyrén, Hoa T Tran, Sabina Kersting, Mattias Mattsson, Juha Ranti, Rogier Mous, Gerrit Jan Veldhuis, Caspar da Cunha-Bang, Mark-David Levin, Valtteri Wirta, Richard Rosenquist, Arnon P. Kater, Carsten Utoft Niemann
Journal: Blood (2024)
IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies Via Modulation of B-1 Cell Subsets in Murine SCD
Authors: Shan Su, Weili Bao, Yunfeng Liu, Patricia Shi, Deepa Manwani, Irina Murakhovskaya, Sally Campbell Lee, Cheryl Lobo, Avital Mendelson, Xiuli An, Hui Zhong, Woelsung Yi, Karina Yazdanbakhsh
Journal: Blood (2024)
The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)
Authors: Anna Maria Sureda Balarí, Javier Nuñez Cespedes, María José Terol Castera, Francisca Maria Hernandez, Eva Domingo Domenech, Fatima De la Cruz Vicente, Miram Moreno, Elena Amutio, Ana Pilar Gonzalez, Raul Cordoba, Maria Carmen Martinez Munoz, Samuel Romero, Mariana Bastos-Oreiro, Antonia Rodriguez Izquierdo, Javier Briones, Richard Greil, Maria Casanova Espinosa, Araceli Rubio, Irit Avivi, Raquel Del Campo, Pilar Gómez, Theodoros P. Vassilakopoulos, Sandra Bašić-Kinda, Sotiros Papageorgiou, Victor Noriega Concepcion, Jose Sanchez Blanco, Blanca Sánchez-González, Izaskun Zeberio, Ramon García
Journal: Blood (2024)
Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
Authors: Sophiya S Sami, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Samer A. Srour
Journal: Blood (2024)
Evaluating the Clinical Impact of Hemoglobinopathy and Hereditary Red Blood Cell Disorder Co-Inheritance in a Cohort of 315 Patients
Authors: Filippo Russo, Anthony Iscaro, Roberta Marra, Antonella Nostroso, Barbara Eleni Rosato, Manuela Dionisi, Federica Maria Esposito, Vanessa D'Onofrio, Mariangela Manno, Valentina Brancaleoni, Simona Leoni, Achille Iolascon, Irene Motta, Immacolata Andolfo, Roberta Russo
Journal: Blood (2024)
Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Authors: Adi Zoref-Lorenz, Elliot J Cahn, Eric Mou, Yucai Wang, Matthew J. Maurer, Andrew L. Feldman, Bri J Negaard, Raphael Mwangi, Gilad Itchaki, Grzegorz S. Nowakowski, Thomas M. Habermann, Brian K. Link, Stephen M. Ansell, Anne J. Novak, Gaurav Goyal, Thomas E. Witzig, James R. Cerhan, Michael B. Jordan
Journal: Blood (2024)
Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
Authors: Kai-Wen Tan, Shanshan Pei, Miao Wang, Lan Dai, Hao Zhang, Chun-Yan Chen, Zhen-Qi Huang, Hai-Ping Dai, Ying Wang, Miao Miao, Yue Han, Xiaowen Tang, Huiying Qiu, Suning Chen, Aining Sun, Depei Wu, Zheng Li, Sheng-Li Xue
Journal: Blood (2024)
Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
Authors: Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood (2024)
CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
Authors: Ibrahim Aldoss, Xiuli Wang, Jianying Zhang, Min Guan, Ruby Espinosa, Vaibhav Agrawal, Andrew Artz, Neguine Sanani, Lior Goldberg, Teresa Kim, Stephanie Kasten, Dileshni Tilakawardane, Mary C Clark, Jamie R Wagner, Jinny Paul, Anthony S. Stein, Vinod Pullarkat, Amandeep Salhotra, Ahmed Aribi, Guido Marcucci, Stephen J. Forman
Journal: Blood (2024)
Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
Authors: Jayanne Forrest, Caren Steinway, Eelia Shaw, Sophia Jan, Banu Aygun, Abena Appiah-Kubi, Nataly Apollonsky, Donna Boruchov, Omar Niss, Biree Andemariam, Kim Smith-Whitley, Symme Trachtenberg, Tanisha Belton
Journal: Blood (2024)
Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes
Authors: Qiaoli Li, Fei Yang, Yuanyi Ling, Zhen Gao, Hong Pan, Weiwang Li, Jingyu Zhao, Liwei Fang, Yajing Chu, Weiping Yuan, Jun Shi
Journal: Blood (2024)
Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
Authors: Cedric Rossi, Jan Boegeholz, Jordan S Goldstein, Shuyu Shi, Shengqin Su, Benoit Tessoulin, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph G. Schroers-Martin, Chih Long Liu, Mari Olsen, Xiaoman Kang, Feng Tian, David Kurtz, Takeshi Sugio, Troy Noordenbos, Marc Andre, Luc-Matthieu Fornecker, Edith Julia, Alexandra Traverse-Glehen, Olivier Casasnovas, Michael S. Binkley, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh
Journal: Blood (2024)
Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
Authors: Abdullah Faisal Deen, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour
Journal: Blood (2024)
Pediatric Nephrology Workforce and Access of Children with Kidney Failure to Transplantation in the United States
Authors: Gabriela Accetta Rojas, Charles E. McCulloch, Timothy P. Copeland, Adrian M. Whelan, Alexandra C. Bicki, Sophia Giang, Barbara A. Grimes, Elaine Ku
Journal: Journal of the American Society of Nephrology (2024)

Key Points Pediatric nephrologists play a critical role in evaluating children with kidney failure for transplant candidacy. Nephrology is one of the pediatric subspecialties with the greatest workforce shortage in the United States. Children residing in states with the highest density of pediatric nephrologists had better access to waitlisting and deceased donor transplantation. Background Nephrology is one of the pediatric subspecialties with the largest workforce shortage in the United States. Waitlist registration is one of the first steps toward kidney transplantation and is facilitated by pediatric nephrologists. The objective of this study was to determine whether state-level density of pediatric nephrologists is associated with access to waitlisting (primary outcome) or kidney transplantation (secondary outcome) in children with kidney failure. Methods Using Cox proportional hazards and logistic regression analyses, we studied children younger than 18 years who developed kidney failure between 2016 and 2020 according to the United States Renal Data System, the national kidney failure registry. The density of pediatric nephrologists (determined by the count of pediatric nephrologists per 100,000 children in each state) was estimated using workforce data from the American Board of Pediatrics and categorized into three groups: &gt;1, 0.5–1, and &lt;0.5. Results We included 4497 children, of whom 3198 (71%) were waitlisted and 2691 (60%) received transplantation. Children residing in states with pediatric nephrologist density &gt;1 had 33% (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.07 to 1.66) and 22% (HR, 1.22; 95% CI, 1.02 to 1.45) better access to waitlisting compared with those residing in states with &lt;0.5 pediatric nephrologist density (reference group) in unadjusted and adjusted analysis, respectively. Pediatric nephrologist density was particularly important for the odds of preemptive waitlisting comparing the highest versus lowest workforce density (adjusted odds ratio, 1.56; 95% CI, 1.02 to 2.41). The adjusted HR was 1.25 (95% CI, 1.00 to 1.55; P = 0.046) for deceased donor transplantation and 1.24 (95% CI, 0.85 to 1.82) for living donor transplantation for children residing in states with pediatric nephrologist density &gt;1 compared with the reference group. Conclusions Children residing in states with higher pediatric nephrologist density had better access to waitlist registration, especially preemptively, and deceased donor transplantation.
Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells
Authors: Ian M. Loveless, Samantha B. Kemp, Kailee M. Hartway, Jacob T. Mitchell, Yuesong Wu, Samuel D. Zwernik, Daniel James Salas-Escabillas, Sydney Brender, Madison George, Yetunde Makinwa, Thais Stockdale, Kendyll Gartrelle, Rohit G. Reddy, Daniel W. Long, Allison Wombwell, Julie M. Clark, Albert M. Levin, David Kwon, Ling Huang, Ralph Francescone, Débora B. Vendramini-Costa, Ben Z. Stanger, Adam Alessio, Andrew M. Waters, Yuehua Cui, Elana J. Fertig, Luciane T. Kagohara, Brian Theisen, Howard C. Crawford, Nina G. Steele
Journal: Clinical Cancer Research (2025)

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) patients with tumors enriched for the basal-like molecular subtype exhibit enhanced resistance to standard-of-care treatments and have significantly worse overall survival compared with patients with classic subtype–enriched tumors. It is important to develop genomic resources, enabling identification of novel putative targets in a statistically rigorous manner. Experimental Design: We compiled a single-cell RNA sequencing (scRNA-seq) atlas of the human pancreas with 229 patient samples aggregated from publicly available raw data. We mapped cell type–specific scRNA-seq gene signatures in bulk RNA-seq (n = 744) and spatial transcriptomics (ST; n = 22) and performed validation using multiplex immunostaining. Results: Analysis of tumor cells from our scRNA-seq atlas revealed nine distinct populations, two of which aligned with the basal subtype, correlating with worse overall survival in bulk RNA-seq. Deconvolution identified one of the basal populations to be the predominant tumor subtype in nondissociated ST tissues and in vitro tumor cell and patient-derived organoid lines. We discovered a novel enrichment and spatial association of CXCL10+ cancer-associated fibroblasts with basal tumor cells. We identified that besides immune cells, ductal cells also express CXCR3, the receptor for CXCL10, suggesting a relationship between these cell types in the PDAC tumor microenvironment. Conclusions: We show that our scRNA-seq atlas (700,000 cells), integrated with ST data, has increased statistical power and is a powerful resource, allowing for expansion of current subtyping paradigms in PDAC. We uncovered a novel signaling niche marked by CXCL10+ cancer-associated fibroblasts and basal tumor cells that could be explored for future targeted therapies.
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction
Authors: Amin Yehya, Jose Lopez, Andrew J Sauer, Jonathan D Davis, Nasrien E Ibrahim, Roderick Tung, Biykem Bozkurt, Gregg C Fonarow, Sana M Al-Khatib
Journal: JACC Heart Failure (2024)
Autopsy of a Drug Withdrawal — The Case of Melphalan Flufenamide
Authors: Bindu Kanapuru, Theresa Carioti, Nicole Gormley, Richard Pazdur
Journal: New England Journal of Medicine (2024)

A December 2022 law introduced a new expedited withdrawal process for accelerated approvals. The first approval withdrawn with this pathway was that of melphalan flufenamide.
Oral switch vs continued intravenous antibiotic therapy in patients with bacteraemia and sepsis: a systematic review and meta-analysis
Authors: Qinyuan Li, Qi Zhou, Jiangbo Fan, Siyuan Huang, Yaolong Chen, Fujian Song, Zhou Fu, Enmei Liu, Daolin Tang, Ling Zeng, Zhengxiu Luo
Journal: Clinical Microbiology and Infection (2024)
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
Authors: Sumit Gupta, Rachel E. Rau, John A. Kairalla, Karen R. Rabin, Cindy Wang, Anne L. Angiolillo, Sarah Alexander, Andrew J. Carroll, Susan Conway, Lia Gore, Ilan Kirsch, Holly R. Kubaney, Amanda M. Li, Jennifer L. McNeer, Olga Militano, Tamara P. Miller, Yvonne Moyer, Maureen M. O’Brien, Maki Okada, Shalini C. Reshmi, Mary Shago, Elizabeth Wagner, Naomi Winick, Brent L. Wood, Tara Haworth-Wright, Faraz Zaman, Gerhard Zugmaier, Sue Zupanec, Meenakshi Devidas, Stephen P. Hunger, David T. Teachey, Elizabeth A. Raetz, Mignon L. Loh
Journal: New England Journal of Medicine (2024)

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.
Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates
Authors: Dongrong Yi, Yongxin Zhang, Jing Wang, Qian Liu, Ling Ma, Quanjie Li, Saisai Guo, Ruifang Zheng, Xiaoyu Li, Xingong Li, Yijie Dong, Shuaiyao Lu, Weiguo Zhang, Xiaozhong Peng, Shan Cen
Journal: Acta Pharmaceutica Sinica B (2024)

The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has posed a global challenge to the control of the coronavirus disease 2019 (COVID-19) pandemic. Therefore, developing countermeasures that broadly protect against SARS-CoV-2 and related sarbecoviruses is essential. Herein, we have developed a lipid nanoparticle (LNP)-encapsulated mRNA (mRNA-LNP) encoding the full-length Spike (S) glycoprotein of SARS-CoV-2 (termed RG001), which confers complete protection in a non-human primate model. Intramuscular immunization of two doses of RG001 in Rhesus monkey elicited robust neutralizing antibodies and cellular response against SARS-CoV-2 variants, resulting in significantly protected SARS-CoV-2-infected animals from acute lung lesions and complete inhibition of viral replication in all animals immunized with low or high doses of RG001. More importantly, the third dose of RG001 vaccination elicited effective neutralizing antibodies against current epidemic XBB and JN.1 strains and similar cellular response against SARS-CoV-2 Omicron variants (BA.1, XBB.1.16, and JN.1) were observed in immunized mice. All these results together strongly support the great potential of RG001 in preventing the infection of SARS-CoV-2 variants of concern (VOCs).
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data
Authors: Alex E Henney, David R Riley, Theresa J Hydes, Matthew Anson, Gema H Ibarburu, Frederick Frost, Uazman Alam, Daniel J Cuthbertson
Journal: Thorax (2024)

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are treatments for type 2 diabetes (T2D). Beyond glucose-lowering and cardiorenal protection, these drugs may protect against pneumonia and sepsis. Aims This study assesses the impact of SGLT2i and GLP-1 RAs on the risk of incident pneumonia and severe sepsis. Methods A retrospective cohort study was conducted using anonymised electronic medical records from TriNetX, a global federated database. Two intention-to-treat analyses were performed, each with two cohorts of adult T2D patients. The first analysis compared individuals prescribed SGLT2i, and the second individuals prescribed GLP-1 RAs, with those prescribed dipeptidyl peptidase-4 inhibitors (DPP-4i). An active comparator new user design was used, with outcomes defined as time-to-incident pneumonia and severe sepsis. Propensity score matching (1:1) was applied to control for potential confounders, and patients were followed for 12 months. Secondary analyses compared SGLT2i and GLP-1 RAs against other glucose-lowering therapies. Results After propensity score matching, 352 687 patients were included in the SGLT2i versus DPP-4i comparison. SGLT2i treatment was associated with a risk reduction in incident pneumonia (HR 0.75 (95% CI 0.73, 0.78)) and severe sepsis (0.75 (0.73, 0.77)). In the GLP-1 RA versus DPP-4i comparison, 331 863 patients were included. GLP-1 RA treatment was associated with a risk reduction in incident pneumonia (0.60 (0.58, 0.62)) and severe sepsis (0.61 (0.59, 0.63)). Conclusion SGLT2i and GLP-1 RAs are associated with a reduced risk of incident pneumonia and severe sepsis in patients with T2D. Further research and focused randomised controlled trials are warranted to explore the broader clinical implications of these treatments.
A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease
Authors: Matthew S. Davids, Christine E. Ryan, Benjamin L. Lampson, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Jennifer L. Crombie, Austin I. Kim, Matthew Weinstock, Josie Montegaard, Heather A. Walker, Claire Greenman, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Steve Lo, Adam J. Olszewski, Jon E. Arnason, Inhye E. Ahn, Jennifer R. Brown
Journal: Journal of Clinical Oncology (2024)

PURPOSE The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type TP53 ; however, due to the chemoimmunotherapy control arm, AMPLIFY excluded patients with high-risk TP53 aberration, for whom current standards of care are continuous Bruton tyrosine kinase inhibitor therapy or alternatively fixed-duration venetoclax-based doublets. AVO has not previously been evaluated in patients with CLL with TP53 aberration. METHODS This investigator-sponsored, multicenter, phase II study enrolled patients with treatment-naïve CLL enriched for high-risk CLL, defined by TP53 aberration (ClinicalTrials.gov identifier: NCT03580928 ). Patients received acalabrutinib, obinutuzumab, and then venetoclax, with each treatment introduced sequentially and in combination, with the duration guided by measurable residual disease (MRD). Patients who achieved undetectable MRD (uMRD) after either 15 or 24 cycles could discontinue treatment. The primary end point was complete remission (CR) with bone marrow uMRD (BM-uMRD) at the start of cycle 16. RESULTS Seventy-two patients were accrued, including 45 patients with TP53 aberration. The CR with BM-uMRD rates at the start of cycle 16 were 42% in patients with TP53 aberration and 42% in all-comers, and the BM-uMRD rates were 71% and 78%, respectively. Hematologic toxicities were mainly low grade, and cardiovascular toxicities and bleeding complications were infrequent. After a median follow-up of 55.2 months, 10 patients had progressed, including four with transformation, and three patients died. Four-year progression-free survival and overall survival for patients with or without TP53 aberration were 70%/96% and 88%/100%, respectively. CONCLUSION AVO was highly active and well tolerated in patients with previously untreated high-risk CLL, supporting its use as a new standard-of-care treatment option.
3MO Efficacy of neoadjuvant pembrolizuamb in early triple-negative breast cancer according to germline BRCA-1/2 mutation
Authors: S.J. Bae, B. Seung Ho, Y. Kook, J.H. Kim, L. Minji, S.G. Ahn, J. Jeong
Journal: Annals of Oncology (2024)
84P A multi-centre analysis of metastatic colorectal cancer diagnosed under the age of 35: A molecularly distinct group?
Authors: C. Williams, A. Jalali, S.P. Ackland, M. Burge, S. Caird, T. Hayes, G. Kim, B. Lee, L.M. Nott, B.B.Y. Ma, S. Mendis, S-A. McLachlan, N. Potasz, N. Rainey, J. Shapiro, C.R. Underhill, R. Wong, S.F. Wong, V. Wong, P. Gibbs
Journal: Annals of Oncology (2024)
668P The Impact of MTAP loss on response to immune checkpoint inhibitors in stage IV NSCLC: A prospective real-world analysis
Authors: A. El-Helali, E.Y-L. Ko, C.H.L. Wong, M. Lecoultre, M.K.L. Chiu, I. Ho, D. Leung, A.W.M. Lee, V.H.F. Lee
Journal: Annals of Oncology (2024)
487P Effect of epithelial-mesenchymal transition status on the efficacy of RAF/MEK clamp and FAK inhibitor combination therapy for KRAS-mutated lung cancer
Authors: A. Yoshimura, M. Horinaka, T. Yaoi, H. Ono, K. Itoh, T. Yamada, K. Takayama, T. Sakai
Journal: Annals of Oncology (2024)
607P Results from a feasibility pilot for integrated TB &amp; lung cancer screening in Vietnam
Authors: A.J. Codlin, T. Dao, P. Trinh, B. Nguyen, H. Pham, L. Le, L. Vo, R. Forse, A. Vo, T. Le, T. Tran, H. Dang, L. Nguyen
Journal: Annals of Oncology (2024)
519P Decoding the unknowns: Tier III alterations in solid tumors from tertiary cancer centre in India
Authors: M. Gurav, P. Gogte, P. Joshi, R. Iyer, K. Vyas, S. Jaiswar, U. Shetty, A. Nair, S. Sawant, A. Rangaiya, M. Mulay, S. Dhanavade, T. Pai, G. Deshpande, N. Karnik, P. Shah, M. Ranade, O. Shetty, S. Desai
Journal: Annals of Oncology (2024)
456P Real-world analysis of usage and efficacy of immune check point inhibitors in recurrent/metastatic head and neck cancers
Authors: K.R. Domadia, N. Pandya, D. Mandlik, D. Patel, K. Jani, P. Patel, P.D. Patel, S. Batham, P.H. Hirapara, V.K. Modi, A. Joshipura, N. Sharma, A. Shah, M. Gandhi, D. Toprani, R. Toprani, K. Patel
Journal: Annals of Oncology (2024)
492P Efficacy and safety of larotrectinib in neurotrophic tyrosine receptor kinase fusion-positive solid tumors: A multicenter retrospective cohort study in Korea
Authors: S. Lee, S. Yoon, W. Choi, H.A. Jung, S.B. Bae, C.G. Kim, H.R. Kim, K-W. Lee, E.J. Kang, K. Shin, S.J. Park, D-J. Lim, S. Park, K-E. Lee, Y. Lee, H.S. Kim, T.J. Kim, M.J. Kim, J.H. Kang
Journal: Annals of Oncology (2024)
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals
Authors: E.P. Hui, P. Sundaresan, H.R. Kim, K. Nguyen Tuan, T. Nicholls, H-L. Teng, J. Li, J. Si, Y.J. Yew, R. Gowindah, C. Stylianou, P-J. Lou
Journal: Annals of Oncology (2024)
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era
Authors: S. Choi, S. Kim, D-Y. Oh, S-A. Im, D-W. Lee, J. Yoon, M.G. Song, J.M. Bae, J. Koh, H.S. Lee, T.M. Kim, T-Y. Kim, H-S. Yun, T-Y. Kim
Journal: Annals of Oncology (2024)
540P Topical steroids for the prevention of radiation dermatitis in breast cancer: A systematic review and network meta-analyses of randomised controlled trials
Authors: S.W. Tse, M. Gojesvic, S.F. Lee, S. Caini, M. Sauder, C. Hircock, A. Wang, W. Chan, K. Corbin, I. Choi, G. Marta, T. Hijal, J. Cao, I. Karam, D. Vesprini, E. Chow, H. Wong
Journal: Annals of Oncology (2024)